

Questionnaire

UK COVID-19 Inquiry: Module 2 - Rule 9 Request to Professor Enitan Carrol - Reference: M2/SAGE/01/EDC

Please provide the following information:

- 1. A brief overview of your qualifications, career history, professional expertise and major publications.**

Qualifications

1984 - 1989

MB ChB

Aberdeen University, Aberdeen, Scotland

October 2000

MD

University of Liverpool, Liverpool, England

Epidemiology, Pathogenesis and Genetic Susceptibility in Meningococcal Disease

Other training and qualifications

November 1993

MRCP (UK)

April 1996

MRCPC (Founder member)

August 2003

Certificate of Completion of Specialist Training in paediatrics with a special interest in Infectious Diseases and Immunology

December 2003

Diploma in Tropical Medicine and Hygiene, University of Liverpool

January 2006

Diploma in Medical Science (Human Immunity), University of Liverpool

November 2010

FRCPC

July 2013

Membership of Institute of Leadership and Management (MInstLM)

December 2013

Post Graduate Certificate in Teaching and Learning in Higher Education (PGCert)

July 2014

Fellow of the Higher Education Academy (FHEA)

Research interests

1. Genetic susceptibility and pathophysiology of invasive meningococcal and pneumococcal disease.
2. Diagnostic markers of bacterial infection.
3. The assessment of the microcirculation in paediatric sepsis.
4. Exploring host response mechanisms in sepsis using proteomics and transcriptomics
5. Paediatric Early Warning Scores

Relevant publications

1) Katikireddi SV, Lal S, Carrol ED, Niedzwiedz CL, Khunti K, Dundas R, Diderichsen F, Barr B.

Unequal impact of the COVID-19 crisis on minority ethnic groups: a framework for understanding and addressing inequalities.

J Epidemiol Community Health. 2021; 75(10):970-974.

2) Powell N, Howard P, Llewelyn MJ, Szakmany T, Albur M, Bond SE, Euden J, Brookes-Howell L, Dark P, Hellyer TP, Hopkins S, McCullagh IJ, Ogden M, Pallmann P, Parsons H, Partridge DG, Shaw DE, Shinkins B, Todd S, Thomas-Jones E, West R, Carrol ED, Sandoe JAT.

Use of Procalcitonin during the First Wave of COVID-19 in the Acute NHS Hospitals: A Retrospective Observational Study.

Antibiotics 2021;10: 516.

3) Llewelyn MJ, Grozeva D, Howard P, Euden J, Gerver SM, Hope R, Heginbotham M, Powell N, Richman C, Shaw D, Thomas-Jones E, West RM, Carrol ED, Pallmann P, Sandoe JAT.

Impact of introducing procalcitonin testing on antibiotic usage in acute NHS hospitals during the first wave of COVID-19 in the UK: a controlled interrupted time series analysis of organization-level data. **J Antimicrob Chemother** 2022 Mar 31;77(4):1189-1196.

2. A list of the groups (i.e. SAGE and/or any of its sub-groups) in which you have been a participant, and the relevant time periods.

SAGE Ethnicity Sub-group: 2019 Novel Coronavirus (Covid-19) August 2020-July2021

3. An overview of your involvement with those groups between January 2020 and February 2022, including:

a. When and how you came to be a participant;

Invited to join 28/8/20 on advice of the then President of the Royal College of Paediatrics and Child Health

b. The number of meetings you attended, and your contributions to those meetings;

Unsure of exact number, but were weekly for first 6 months at least

c. Your role in providing research, information and advice.

Contributed to meetings and papers as appropriate.

4. A summary of any documents to which you contributed for the purpose of advising SAGE and/or its related subgroups on the Covid-19 pandemic. Please include links to those documents where possible.

Drivers of the higher COVID-19 incidence, morbidity and mortality among minority ethnic groups

[Drivers of the higher COVID-19 incidence, morbidity and mortality among minority ethnic groups, 23 September 2020 - GOV.UK \(www.gov.uk\)](#)

5. A summary of any articles you have written, interviews and/or evidence you have given regarding the work of the above-mentioned groups and/or the UK's response to the Covid-19 pandemic. Please include links to those documents where possible.

[Drivers of the higher COVID-19 incidence, morbidity and mortality among minority ethnic groups, 23 September 2020 - GOV.UK \(www.gov.uk\)](#)

6. Your views as to whether the work of the above-mentioned groups in responding to the Covid-19 pandemic (or the UK's response more generally) succeeded in its aims. This may include, but is not limited to, your views on:

- a. The composition of the groups and/or their diversity of expertise;**
Groups was diverse and included relevant expertise as well as invited experts as necessary.
- b. The way in which the groups were commissioned to work on the relevant issues;**
Individuals with most relevant expertise invited to lead aspects of work.
- c. The resources and support that were available;**
Significant support from secretariat and seconded research fellows.

d. The advice given and/or recommendations that were made;

[Factors influencing COVID-19 vaccine uptake among minority ethnic groups, 17 December 2020 - GOV.UK \(www.gov.uk\)](#)

[Evidence summary of impacts to date of public health communications to minority ethnic groups and related challenges, 23 September 2020 - GOV.UK \(www.gov.uk\)](#)

[Housing, household transmission and ethnicity, 26 November 2020 - GOV.UK \(www.gov.uk\)](#)

e. The extent to which the groups worked effectively together;

Groups worked well together, and Chair (Prof Kamlesh Khunti) was on main SAGE group

f. The extent to which applicable structures and policies were utilised and/or complied with and their effectiveness.

Worked effectively together. Good communication.

7. Your views as to any lessons that can be learned from the UK's response to the Covid-19 pandemic, in particular relating to the work of the above-mentioned groups. Please describe any changes that have already been made, and set out any recommendations for further changes that you think the Inquiry should consider making.

The group worked very well together, and drew on relevant expertise. It was inclusive, and was well supported by the secretariat.

8. A brief description of documentation relating to these matters that you hold (including soft copy material held electronically). Please retain all such material. I am not asking for you to provide us with this material at this stage, but I may request that you do so in due course.

Copies of documents listed above and my own notes of meetings.